E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10052596 |
E.1.2 | Term | Nosocomial pneumonia |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
- To determine the pharmacokinetic (PK) profile of aerosolized amikacin administered via the PDDS Clinical in patients with nosocomial pneumonia caused by gram-negative organisms - To evaluate the safety and tolerability of aerosolized amikacin administered via PDDS Clinical in patients with nosocomial pneumonia caused by gram-negative organisms |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Males and non-pregnant, non-lactating females, 18 years of age or older. For females of child-bearing potential, one of the following medically acceptable contraceptive methods must be used: a) Double-barrier methods of contraception (e.g. condoms plus spermicidal foam) b) Intrauterine contraceptive device c) Approved pharmaceutical contraceptive product (e.g. birth control pills or patches, longterm injectable or implantable hormonal contraceptive) 2. Intubated and mechanically-ventilated (patients who have had a tracheostomy may be considered as possible study participants) 3. Diagnosis of pneumonia defined as presence of a new or progressive infiltrate(s) on chest radiograph and presence of gram-negative organisms by gram stain of respiratory secretions (tracheal aspirate, BAL, mini-BAL, PBS) plus at least 2 of the following: a) Fever, defined as an oral temperature of > 38.0°C (100.4°F) or a rectal/core temperature > 39.0°C (102.2°F), or hypothermia, defined as a rectal/core body temperature of < 35.0°C (95.2°F) b) Leukocyte count ≥ 10,000/mm3 or ≤ 4,500/mm3 c) New onset of purulent sputum production or respiratory secretions, or a change in the character of sputum 4. Expected to remain intubated and mechanically-ventilated for at least three days after the start of study treatment 5. Be willing and able to give informed consent. If the patient is unable, the patient’s LAR may provide written consent as approved by the IRB/IEC. |
|
E.4 | Principal exclusion criteria |
1. Primary lung cancer or another malignancy metastatic to the lungs 2. Known or suspected active tuberculosis, cystic fibrosis, AIDS, or Pneumocystis carinii pneumonia 3. Receiving immunosuppressive therapy, defined as chronic treatment with known immunosuppressant medications (including chronic treatment with >10 mg/day of systemic prednisone or equivalent) 4. BMI ≥ 30 5. Burns greater than 40% of total body surface area 6. Any known chronic liver disease 7. Known local or systemic hypersensitivity to amikacin or aminoglycosides 8. Diagnosis of end stage renal failure or currently on dialysis 9. Severe hypoxemia as defined by Screening PaO2/FiO2 < 200 10. Serum creatinine > 2 mg/dL 11. Screening serum albumin level < 2 g/dL 12. Neutropenia (Screening ANC < 103 neutrophils/cc) 13. Any use of amikacin by any route within seven days prior to start of study treatment 14. Is participating in or has participated in other investigational trials within the last 28 days prior to study treatment 15. Presence of any concomitant condition that, in the opinion of the investigator, would preclude completion of study evaluations or make it unlikely that the contemplated course of therapy and follow-up could be completed. 16. Known respiratory colonization with amikacin-resistant gram negative rods. Amikacin resistance is defined as an MIC > 32 mcg/mL. 17. Community-acquired pneumonia |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Pharmacokinetic and Safety
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 8 |